Jennifer Fergeson, DO
Allergy & Immunology · Sarasota, FLNPI 1326337577
Payments from drug & device makers
Across 685 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- GSK$1K
- CSL Behring$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $5K from 31 others
What the payments were for
- Consulting fees$170%
- Food & beverage$13,864100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 72 | $2,163 |
| AstraZeneca | 111 | $2,057 |
| GSK | 98 | $1,493 |
| CSL Behring | 54 | $1,098 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,097 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $1,078 |
| Novartis | 31 | $674 |
| Genentech USA, Inc. | 33 | $549 |
| AbbVie | 17 | $350 |
| Optinose US, Inc. | 17 | $345 |
| Pfizer | 19 | $325 |
| Kaleo, Inc. | 16 | $268 |
| Biocryst US Sales Co., LLC | 9 | $265 |
| Octapharma USA, Inc. | 13 | $256 |
| Amgen(2 entities) | 12 | $245 |
| Grifols USA, LLC | 12 | $238 |
| Alk-abello, Inc | 11 | $209 |
| Shire North American Group Inc | 13 | $194 |
| Pharming Healthcare, Inc. | 10 | $188 |
| Mylan Specialty L.p. | 5 | $103 |
| Incyte Corporation | 4 | $82 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $79 |
| GC Biopharma USA, Inc. | 3 | $70 |
| Boehringer Ingelheim | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| LEO Pharma Inc. | 2 | $53 |
| Covis Pharma GmbH | 2 | $43 |
| ADMA Biomanufacturing LLC | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $27 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| Circassia Inc. | 2 | $24 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Merck | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $14 |
How this compares
$13,881 in reported general payments places this provider in the 70th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $87,299 |
| Dupixent SyringeDupilumab | 12 | $44,578 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,553 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,628 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,138 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,861 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $4,430 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $4,366 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $4,223 |
| Azelastine Hcl | 182 | $4,182 |
| Ipratropium Bromide | 113 | $3,646 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,275 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,231 |
| Fluticasone Propionate | 195 | $2,561 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 28 | $2,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,493 | $96,926125 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,057 | $13,82828 claims |
| Boehringer IngelheimSpiriva Respimat | $69 | $9,13812 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $2,21917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Sarasota
- Sharlene LlanesSarasota$18K
- Jaime LandmanAventura$3.9M
- Ileana RodicioMiami$3.8M
- Jose CarpioMiami$3.6M
- Michael KohenDaytona Beach$3.6M
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
- Ronald SaffTallahassee$1.2M
- Shahnaz FattehPlantation$1M
- Seong ChoTampa$969K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.